A generalised model for individualising a treatment recommendation based on group-level evidence from randomised clinical trials

BMJ Open

Volumn 3, Issue 8, 2013, Pages

  Marcucci, Maura ^a   Sinclair, John C ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ROSUVASTATIN; WARFARIN;

ARTICLE; CARDIOEMBOLIC STROKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; GENERALIZED MODEL; HEART ATRIUM FIBRILLATION; HUMAN; MODEL; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT INDICATION;

EID: 84885332950     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003143     Document Type: Article

References (21)

1. Wong SS, Wilczynski NL, Morgan D, et al Developing optimal search strategies for detecting sound clinical prediction studies in MEDLINE. AMIA Annu Symp Proc 2003:728-32.
2. Holland JL, Wilczynski NL, Haynes RB; Hedges Team. Optimal search strategies for identifying sound clinical prediction studies in EMBASE. BMC Med Inform Decis Mak 2005;5:11.
3. Website for accessing an up-to-date register of critically-appraised clinical prediction guides, searchable by topic. http://plus.mcmaster.ca/ evidenceupdates
4. Sinclair JC, Cook RJ, Guyatt G.H., et al When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol 2001;54:253-62. (Pubitemid 32153869)
5. Vickers AJ, Kattan MW, Sargent D. Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials 2007;8:14.
6. Dorresteijn JA, Visseren FL, Ridker P.M., et al Estimating treatment effects for individual patients based on the results of randomized trials. BMJ 2011;343:d5888.
7. Glasziou PP, Irwig LM An evidence-based approach to individualizing treatment. BMJ 1995;311:1356-9.
8. Ridker PM, Danielson E, Fonseca F.A., et al Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
9. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
10. Ridker PM, Buring JE, Rifai N, et al Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 2007;297:611-19.
11. Hart RG, Pearce LA, Aguilar MI Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67. (Pubitemid 351650486)
12. Gage BF, Waterman AD, Shannon W, et al Validation of clinical classification schemes for predicting stroke. JAMA 2001;285:2864-70.
13. Gage BF, Yan Y, Milligan P.E., et al Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial fibrillation (NRAF). Am Heart J 2006;151:713-19. (Pubitemid 43290267)
14. McAlister FA, Straus SE, Guyatt G.H., et al Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group. JAMA 2000;283:2829-36. (Pubitemid 30387829)
15. LaHaye SA, Gibbens SL, Ball D.G., et al A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation. Eur Heart J 2012;33:2163-71.
16. Ioannidis JP, Garber AM Individualized cost-effectiveness analysis. PLoS Med 2011;8:e1001058.
17. Mark DB, Hlarky MA, Califf R.M., et al Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24.
18. Miller CS, Grandi SM, Shimony A, et al Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012;110:453-60.
19. Stacey D, Bennett CL, Barry M.J., et al Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2011;10:CD001431.
20. Walter SD, Sinclair JC Uncertainty in the minimum event risk to justify treatment was evaluated. J Clin Epidemiol 2009;62: 816-24.
21. Glick HA, Briggs AH, Polsky D. Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses. Expert Rev Pharmacoecon Outcomes Res 2001;1:25-36. (Pubitemid 34649743)